<DOC>
	<DOCNO>NCT01955239</DOCNO>
	<brief_summary>Rationale : Radiation-induced parotid gland dysfunction , often lead xerostomia most-frequently occur side-effect major impact patient-reported quality life radiotherapy head neck cancer ( HNC ) . Therefore , treatment HNC currently optimize minimize mean dose parotid gland . Though resulted significant reduction toxicity , 30 % -40 % patient still develop sustained parotid gland dysfunction xerostomia . However , animal study investigator find dose sub-volume gland contain parotid gland stem cell well predictor dysfunction mean dose whole gland . Subsequently , find confirm retrospective analysis patient . Therefore , reduction dose specifically sub-volume parotid glands patient expect reduce risk parotid gland dysfunction xerostomia . Objective : To test hypothesis parotid gland stem cell spar intensity modulate radiotherapy HNC patient reduce risk parotid gland dysfunction xerostomia compare conventional parotid gland spar intensity modulate radiotherapy . Study design : Double-blind prospective randomize trial ( 51 patient per arm ) . Study population : Patients treat tumours head-and-neck region curative radiotherapy , without addition chemotherapy cetuximab . Intervention : Patients randomize experimental arm receive treatment radiation dose parotid gland re-distributed minimize dose sub-volume contain stem cell , keep mean dose parotid gland whole . Main study parameters/endpoints : Primary endpoint parotid gland salivary secretion . Secondary endpoint patient- physician-rated xerostomia .</brief_summary>
	<brief_title>Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Squamous cell carcinoma originate mucosa head neck area nasopharyngeal carcinoma originate nasopharynx ; The radiotherapy include prophylactic therapeutic irradiation side neck ( least level II IV ) ; Age â‰¥ 18 year ; WHO performance 02 ; To reduce uncertainty assessment relative flow treatment , pretreatment parotid gland saliva production stimulate 5 % citric acid exceed &gt; 0.1 ml/min Postoperative radiotherapy ; Previous radiotherapy head neck region ( reirradiation ) ; Unilateral radiotherapy ; Primary salivary gland tumour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>IMRT</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Parotid gland</keyword>
</DOC>